Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
This prospective observational study focuses on VSP in TA patients treated with tocilizumab. Although tocilizumab was effective in alleviating inflammation and disease activity, approximately 47.3% of TA patients receiving tocilizumab showed VSP during the follow-up period. This finding was consistent with those of previous reports, which did not attract enough attention (Summarized in Supplementary Table S5). Furthermore, C3 was a predictive factor for VSP, with an AUC of 0.825 in 1 year.
Highlights ● NPSLE is not the only answer to CNS symptoms in patients with SLE overlapping SSc. ● Distinguishing between RPLS due to SRC and NPSLE is critical for the patient’s prognosis. A 17-year-old female patient with a one-and-a-half-year history of SSc and SLE was admitted to our rheumatology department.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.